Novo Nordisk A/S $NVO Shares Sold by LRT Capital Management LLC

LRT Capital Management LLC cut its holdings in Novo Nordisk A/S (NYSE:NVO) by 70.6% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 6,234 shares of the company’s stock after selling 14,988 shares during the period. LRT Capital Management LLC’s holdings in Novo Nordisk A/S were worth $317,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of the business. Aurora Investment Counsel boosted its stake in Novo Nordisk A/S by 14.8% during the 4th quarter. Aurora Investment Counsel now owns 44,385 shares of the company’s stock valued at $2,258,000 after purchasing an additional 5,706 shares during the period. Avidity Partners Management LP acquired a new position in Novo Nordisk A/S during the 4th quarter valued at about $3,424,000. Brown Advisory Inc. boosted its stake in Novo Nordisk A/S by 5.8% during the 4th quarter. Brown Advisory Inc. now owns 113,301 shares of the company’s stock valued at $5,765,000 after purchasing an additional 6,261 shares during the period. Aigen Investment Management LP acquired a new position in Novo Nordisk A/S during the 4th quarter valued at about $861,000. Finally, Altrafin AG acquired a new position in Novo Nordisk A/S during the 4th quarter valued at about $8,913,000. 11.54% of the stock is owned by institutional investors and hedge funds.

Novo Nordisk A/S Stock Down 0.1%

NYSE NVO opened at $43.90 on Friday. The company has a debt-to-equity ratio of 0.59, a current ratio of 0.79 and a quick ratio of 0.56. The company’s 50 day simple moving average is $42.28 and its 200 day simple moving average is $46.00. Novo Nordisk A/S has a 12 month low of $35.12 and a 12 month high of $81.44. The company has a market capitalization of $196.02 billion, a P/E ratio of 10.31, a PEG ratio of 3.92 and a beta of 0.78.

Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Tuesday, March 31st. The company reported $1.03 EPS for the quarter. Novo Nordisk A/S had a net margin of 37.23% and a return on equity of 63.31%. The business had revenue of $10.85 billion for the quarter. Equities research analysts expect that Novo Nordisk A/S will post 3.45 earnings per share for the current fiscal year.

Key Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: UK regulators approved Novo Nordisk’s daily Wegovy pill, making it the first GLP-1 weight-loss tablet approved in the UK. That expands the company’s obesity franchise beyond injections and could open a new growth channel. UK approves Novo weight-loss pill to edge open European market
• Positive Sentiment: Several follow-up reports highlighted the UK approval as a milestone that could help Novo regain momentum in the obesity market and broaden access to Wegovy through private prescriptions. Novo Nordisk Wegovy pill becomes first daily GLP-1 weight-loss pill approved in the UK
• Positive Sentiment: Analysts also raised FY2026 EPS estimates slightly, signaling still-solid earnings expectations despite recent share-price weakness. Novo Nordisk A/S Trading Down 0.1%
• Neutral Sentiment: Some commentary on the “Wegovy pill” said the approval is encouraging but not yet enough to make certain investors buy, suggesting the market may want more proof of commercial impact before re-rating the stock. Novo Nordisk: Wegovy Pill Is Encouraging But Still Not Enough To Make Me Buy
• Negative Sentiment: Novo Nordisk disclosed an IT security incident involving unauthorized access to internal systems and potential data copying, which could pressure investor confidence even though the company said operations were not materially affected. Novo Nordisk hit by cyber incident, probes data breach
• Negative Sentiment: Another report said some U.S. employers may drop GLP-1 obesity-drug coverage in 2027, a potential headwind for long-term demand and reimbursement for Wegovy and rival products. Some US employers to drop coverage of GLP-1 obesity drugs in 2027 as use increases

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on NVO. TD Cowen lowered shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating and set a $42.00 target price for the company. in a research note on Tuesday, March 10th. Wall Street Zen raised shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Saturday, May 16th. Deutsche Bank Aktiengesellschaft lowered shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Monday, February 23rd. Sanford C. Bernstein began coverage on shares of Novo Nordisk A/S in a research note on Wednesday, March 18th. They set an “outperform” rating and a $175.00 target price for the company. Finally, Wolfe Research began coverage on shares of Novo Nordisk A/S in a research note on Thursday, March 26th. They set a “peer perform” rating for the company. Four equities research analysts have rated the stock with a Buy rating, eighteen have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Novo Nordisk A/S has a consensus rating of “Hold” and an average target price of $65.56.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.